Arcus Biosciences, Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

RCUS$18.67-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In millions, except per share amounts)

	September 30,2026	December 31,2025
ASSETS
Current assets:
Cash and cash equivalents	$151	$222
Marketable securities	479	759
Receivable from collaboration partners	18	11
Prepaid expenses and other current assets	16	15
Total current assets	664	1,007
Long-term marketable securities	64	29
Property and equipment, net	33	40
Other noncurrent assets	57	63
Total assets	$818	$1,139
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ($13 and $24 to a related party)	$44	$42
Deferred revenue ($6 and $35 to a related party)	14	35
Other current liabilities	141	154
Total current liabilities	199	231
Deferred revenue, noncurrent ($18 and $43 to a related party)	34	43
Long-term debt	102	99
Other noncurrent liabilities	125	135
Commitments
Stockholders’ equity:
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 127.6 shares in 2026 and 125.3 shares in 2025 issued and outstanding	2,192	2,116
Accumulated deficit	(1,832)	(1,485)
Accumulated other comprehensive loss	(2)	—
Total stockholders’ equity	358	631
Total liabilities and stockholders’ equity	$818	$1,139

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.